InMed receives Nasdaq delisting notice for bid price non-compliance; hearing set for Oct 31, 2024

InMed Pharmaceuticals Inc.

Nasdaq Staff issued delisting notice on Sept 17, 2024, after company failed to meet minimum $1.00 bid price by Sept 16, 2024 compliance deadline.
Company timely filed an appeal; hearing before Nasdaq Listing Qualifications Panel scheduled for October 31, 2024.
Appeal stays delisting pending panel decision; panel may grant up to 180 additional calendar days to regain compliance.
No guarantee extension will be granted or that outcome will be favorable; shares risk suspension or delisting.
Previously received 180-day extension on March 19, 2024 to cure deficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.